1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC)
    Meeting Abstract

    O'Cearbhaill, R. E.; McMeekin, D. S.; Mantia-Smaldone, G.; Gunderson, C.; Sabbatini, P.; Cattaruzza, F.; Fischer, M.; Kapoun, A. M.; Xu, L.; Dupont, J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Clinical activity of anti -programmed death-1 (PD-1) agents in acral and mucosal melanoma
    Meeting Abstract

    Munhoz, R. R.; Shoushtari, A. N.; Kuk, D.; Ott, P. A.; Johnson, D. B.; Tsai, K. K.; Rapisuwon, S.; Eroglu, Z.; Sullivan, R. J.; Luke, J. J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Efficacy of sorafenib in patients with desmoid-type fibromatosis
    Meeting Abstract

    Munhor, R. R.; Lefkowitz, R. A.; Kuk, D.; Dickson, M. A.; D'Angelo, S. P.; Keohan, M. L.; Chi, P.; Crago, A. M.; Maki, R. G.; Schwartz, G. K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction
    Meeting Abstract

    Merlini, G.; Liedtke, M.; Landau, H. J.; Comenzo, R. L.; Sanchorawala, V.; Weiss, B. M.; Zonder, J. A.; Schonland, S.; Guthrie, S. D.; Walling, J.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma
    Meeting Abstract

    Middleton, M. R.; Steven, N. M.; Evans, T. J.; Infante, J. R.; Sznol, M.; Mulatero, C.; Hamid, O.; Shoushtari, A. N.; Shingler, W.; Johnson, A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI)
    Meeting Abstract

    Menzies, A. M.; Johnson, D. B.; Ramanujam, S.; Atkinson, V.; Wong, A. N. M.; Park, J. J.; McQuade, J. L.; Shoushtari, A. N.; Tsai, K. K.; Eroglu, Z.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Characteristics of ponatinib (PON) therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients (pts) in real-world (RW) clinical practice compared to the PACE trial
    Meeting Abstract

    Mauro, M. J.; McGarry, L.; Yang, M.; Lustgarten, S.; Huang, H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Comparison of PACE clinical trial versus real-world (RW) ponatinib (PON) prescribing and duration of therapy (DOT) in US chronic-phase chronic myeloid leukemia (CP-CML) patients (pts)
    Meeting Abstract

    Mauro, M. J.; McGarry, L.; Yang, M.; Lustgarten, S.; Huang, H.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Cytokine release syndrome (CRS) in patients treated with NY-ESO-1(c259) TCR
    Meeting Abstract

    Mackall, C.; D'Angelo, S. P.; Cristea, M. C.; Odunsi, K.; Norry, E.; Pandite, L.; Holdich, T.; Kari, G.; Ramachandran, I. R.; Ribeiro, L.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save